QuidelOrtho [QDEL] vs Abbott Laboratories [ABT] Detailed Stock Comparison

QuidelOrtho Corporation

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: QuidelOrtho Corporation wins in 6 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric QuidelOrtho Corporation Abbott Laboratories Better
P/E Ratio (TTM) N/A 25.97 N/A
Price-to-Book Ratio 0.42 3.09 QuidelOrtho Corporation
Debt-to-Equity Ratio 148.60 26.79 Abbott Laboratories
PEG Ratio 4.15 -1.41 QuidelOrtho Corporation
EV/EBITDA 6.23 13.74 QuidelOrtho Corporation
Profit Margin (TTM) -41.46% 13.90% Abbott Laboratories
Operating Margin (TTM) 4.01% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 4.01% 16.50% Abbott Laboratories
Return on Equity -46.15% 12.36% Abbott Laboratories
Return on Assets (TTM) 1.27% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-83.00M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -57.55% -35.92% Abbott Laboratories
Price-to-Sales Ratio (TTM) 0.30 3.57 QuidelOrtho Corporation
Enterprise Value $3.50B $166.96B Abbott Laboratories
EV/Revenue Ratio 1.28 3.70 QuidelOrtho Corporation
Gross Profit Margin (TTM) 44.28% N/A N/A
Revenue per Share (TTM) $40 $26 QuidelOrtho Corporation
Earnings per Share (Diluted) $-16.69 $3.57 Abbott Laboratories
Beta (Stock Volatility) 0.92 0.78 Abbott Laboratories
Short % of Float 31.16% 1.53% Abbott Laboratories

QuidelOrtho Corporation vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

QDEL
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
QuidelOrtho Corporation2.33%10.84%7.00%-41.19%-49.91%-53.82%
Abbott Laboratories0.02%0.35%-0.65%-23.79%-31.15%-29.97%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
QuidelOrtho Corporation-57.55%-84.89%-87.49%-22.50%-11.19%34.37%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: QuidelOrtho Corporation vs Abbott Laboratories

MetricQDELABT
Market Information
Market Cap i$765.24M$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i3,727,55913,495,583
90 Day Avg. Volume i2,559,68312,934,461
Last Close$13.60$86.99
52 Week Range$9.92 - $35.58$81.97 - $139.06
% from 52W High-61.78%-37.44%
All-Time High$306.72 (Aug 03, 2020)$142.60 (Dec 27, 2021)
% from All-Time High-95.57%-39.00%
Growth Metrics
Quarterly Revenue Growth0.02%0.08%
Quarterly Earnings Growth0.02%-0.19%
Financial Health
Profit Margin (TTM) i-0.41%0.14%
Operating Margin (TTM) i0.04%0.17%
Return on Equity (TTM) i-0.46%0.12%
Debt to Equity (MRQ) i148.6026.79
Cash & Liquidity
Book Value per Share (MRQ)$28.28$30.02
Cash per Share (MRQ)$2.50$5.14
Operating Cash Flow (TTM) i$105.20M$10.80B
Levered Free Cash Flow (TTM) i$233.88M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: QuidelOrtho Corporation vs Abbott Laboratories

MetricQDEL (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A25.97
Forward P/E i4.1515.29
PEG Ratio i4.15-1.41
Price to Sales (TTM) i0.303.57
Price to Book (MRQ) i0.423.09
Market Capitalization
Market Capitalization i$765.24M$160.70B
Enterprise Value i$3.50B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i1.283.70
Enterprise to EBITDA i6.2313.74
Risk & Other Metrics
Beta i0.920.78
Book Value per Share (MRQ) i$28.28$30.02

Financial Statements Comparison: QuidelOrtho Corporation vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricQDEL (2025)ABT (2025)
Revenue/Sales i2.73B44.33B
Cost of Goods Sold i1.46B19.32B
COGS % of Revenue i53.3%43.6%
Gross Profit i1.27B25.01B
Gross Margin i46.7%56.4%
Research & Development i186.20M2.94B
Operating Income (EBIT) i54.80M8.05B
Operating Margin i2.0%18.2%
EBITDA i488.50M12.03B
EBITDA Margin i17.9%27.1%
Pre-Tax Income i-1.11B8.47B
Pre-Tax Income % of Revenue i-40.6%19.1%
Income Tax i24.10M1.94B
Income Tax % of Revenue i0.9%4.4%
Net Income (Profit) i-1.13B6.52B
Profit Margin i-41.5%14.7%

Balance Sheet & Liquidity Metrics

MetricQDEL (2025)ABT (2025)
Cash & Equivalents i169.80M8.52B
Total Current Assets i1.45B26.00B
Total Current Assets % of Revenue i53.0%58.6%
Total Current Liabilities i966.10M16.50B
Total Current Liabilities % of Revenue i35.4%37.2%
Long-Term Debt i2.63B10.83B
Long-Term Debt % of Revenue i96.2%24.4%
Total Shareholders Equity i1.92B52.77B
Retained Earnings i-996.00M49.78B
Retained Earnings % of Revenue i-36.5%112.3%
Property, Plant & Equipment i1.06B17.57B

Cash Flow Statement Comparison

MetricQDEL (2025)ABT (2025)
Operating Cash Flow i-770.50M10.80B
Operating Cash Flow % of Revenue i-28.2%24.4%
Capital Expenditures i-188.20M-2.17B
Free Cash Flow i-83.00M7.40B
FCF Margin i-3.0%16.7%
Debt Repayment i-2.41B-1.50B
Common Stock Repurchase i0-893.00M

Short Interest & Institutional Ownership Analysis

MetricQDELABT
Shares Short i12.79M23.83M
Short Ratio i7.641.93
Short % of Float i31.16%1.53%
Shares Outstanding i67.93M1.74B
Float Shares i63.58M1.73B
% Held by Insiders i1.01%0.54%
% Held by Institutions i115.01%82.23%
% Held by Public i-16.02%17.23%

Dividend Analysis & Yield Comparison: QuidelOrtho Corporation vs Abbott Laboratories

MetricQDELABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026